News

A benzodiazepine analog produced positive results in a mouse study.

Several companies are developing new drugs to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), a formerly obscure condition that is getting an increasing amount of attention.

An optimistic outlook on the future of the biosimilar market driving down pharmaceutical drug spend.

How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and patients, according to Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca

Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora says to keep the following in mind as AI use accelerates.

Ways AI is increasingly used in healthcare and how it can benefit healthcare decision makers, according to Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora.

Only a small group of patients have started the process to receive the new gene therapies for sickle cell disease, says Kevin Niehoff, Pharm.D., of IPD Analytics.

Two years after treatment, both girls show normal motor function and no signs of spinal muscular atrophy symptoms.

A closer look at the available PrEP options available in the United States.

Here’s what you missed this week on Managed Healthcare Executive.

The regimen has shown promise in preventing graft-versus-host disease in patients who received a haploidentical stem cell transplant.

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.

One area of interest is whether ketogenic diets, which are high in fat and low in carbohydrates, might be helpful to people with treatment-resistant depression.

The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.

Apitegromab works by targeting a protein called myostatin that limits muscle growth and is designed to be used alongside existing spinal muscular atrophy (SMA) treatments.

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of those who received placebo.

More research on clinical meaningfulness is on the way, according to Stephanie Graff, M.D., FACP, FASCO.

Early trial data of two virally suppressed, breast-feeding women with HIV shows that there may be less of a risk of HIV transmission during breastfeeding than previously believed.

Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.

Here’s what you missed this week on Managed Healthcare Executive.

Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute, explains the importance of the term “clinically meaningful” and shares some of the ways it can be defined.

The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by the end of this year.

Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.

Luke Greenwalt, MBA, vice president and lead, IQVIA Market Access Center of Excellence, has joined the editorial advisory board of Managed Healthcare Executive.

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful approach can head off ethical problems and optimize efficiency.

Although many women are living longer after a breast cancer diagnosis, inequalities persist.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Payers and providers are figuring out ways to overcome the transportation barriers that get in the way of people receiving healthcare.

Sean M. Oser, M.D., M.P.H., an associate professor in the Department of Family Medicine at the University of Colorado School of Medicine, discussed diabetes management and quality measures in a Managed Healthcare Executive K-Cast video series.